Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Temsirolimus | |
| Synonyms |
Rapamycin Analog temsirolimus TEMSIROLIMUS Temsirolimus Rapamycin Analog CCI-779 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin Cell Cycle Inhibitor 779 CCI-779 Rapamycin Analog CCI-779 Torisel |
|
| Definitions |
An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1844 |
|
| Accepted_Therapeutic_Use_For |
Renal Cell Carcinoma Advanced renal cell carcinoma
|
|
| ALT_DEFINITION |
A drug used to treat advanced renal cell carcinoma (a type of kidney cancer). It is also being studied in the treatment of other types of cancer. Temsirolimus blocks a protein involved in cell division, and may kill cancer cells. It is a type of rapamycin analog and a type of serine/threonine kinase inhibitor.
|
|
| CAS_Registry |
162635-04-3
|
|
| Chemical_Formula |
C56H87NO16
|
|
| code |
C1844
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc
|
|
| DEFINITION |
An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.
|
|
| Display_Name |
Temsirolimus
|
|
| FDA_UNII_Code |
624KN6GM2T
|
|
| FULL_SYN |
Rapamycin Analog temsirolimus TEMSIROLIMUS Temsirolimus Rapamycin Analog CCI-779 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin Cell Cycle Inhibitor 779 CCI-779 Rapamycin Analog CCI-779 Torisel
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Temsirolimus
|
|
| Legacy Concept Name |
CCI-779
|
|
| Maps_To |
Temsirolimus
|
|
| NCI_Drug_Dictionary_ID |
43369
|
|
| NSC Number |
683864
|
|
| PDQ_Closed_Trial_Search_ID |
43369
|
|
| PDQ_Open_Trial_Search_ID |
43369
|
|
| Preferred_Name |
Temsirolimus
|
|
| prefixIRI |
Thesaurus:C1844
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| UMLS_CUI |
C1707080
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |